December 26, 2019

Letter of Intent for RBM-007 Licensing Agreement for Age-related Macular Degeneration

TOKYO, December 26, 2019 - RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TSE-Mothers: 4591, President and CEO: Yoshikazu Nakamura, Ph.D.) today announced that RIBOMIC has signed a letter of intent with AJU Pharm, a Korean pharmaceutical company, for RBM-007 licensing agreement for age-related macular degeneration in the territory of Korea and Southeast Asia. The final agreement is scheduled for next spring and RIBOMIC is expected to receive up to $ 6 million licensing consideration.

Upon licensing agreements being executed, RIBOMIC also plan to disclose the impact on our business results for the fiscal year ending March 31, 2020.

Contacts for inquiries or additional information:
RIBOMIC Inc.
Corporate Planning Department
ir.inquiry@ribomic.com

AJU PHARM
Since established in 1953, AJU Pharm has a corporate philosophy of striving not only to treat patients but also to make healthy people live healthier and happier. AJU Pharm manufactures and sells medicine mainly in ophthalmology and is a total healthcare company that supplies medical devices and health foods in Korea.

http://www.ajupharm.co.kr/xe/